Transforming Growth Factor-Beta Inhibition Reduces Progression of Early Choroidal Neovascularization Lesions in Rats: P17 and P144 Peptides

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Zarranz Ventura, Javier ^a,b   Fernández Robredo, Patricia ^a   Recalde, Sergio ^a   Salinas Alamán, Angel ^b   Borrás Cuesta, Francisco ^c   Dotor, Javier ^d   García Layana, Alfredo ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

^d Digna Biotech   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CYCLOOXYGENASE 2; GELATINASE A; GELATINASE B; INTERLEUKIN 6; LYSYLARGINYLISOLEUCYLTRYPTOPHYLPHENYLALANYLISOLEUCYLPROPYLARGINYLSERYLSERYLTRYPTOPHYLTYROSYLGLUTAMYLARGINYLALANINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SMAD2 PROTEIN; SOMATOMEDIN C; THREONYLSERYLLEUCYLASPARTYLALANYLSERYLISOLEUCYLTRYPTOPHYLALANYLMETHIONYLMETHIONYLGLUTAMINYLASPARAGINE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; P17 PEPTIDE; PEPTIDE; PEPTIDE FRAGMENT; TGF BETA1 TYPE III RECEPTOR (730 743), HUMAN; TGF-BETA1 TYPE III RECEPTOR (730-743), HUMAN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; COX 2 GENE; DIODE LASER; ENZYME ACTIVITY; GENE EXPRESSION; IGF 1 GENE; IL6 GENE; MMP 2 GENE; MMP 9 GENE; NONHUMAN; PAI 1 GENE; PROTEIN EXPRESSION; RAT; RETINA FLUORESCEIN ANGIOGRAPHY; SUBRETINAL NEOVASCULARIZATION; TGF BETA GENE; TNF ALPHA GENE; TREATMENT OUTCOME; VEGF GENE; ANIMAL; DISEASE COURSE; DRUG ANTAGONISM; DRUG EFFECT; FLUORESCENCE ANGIOGRAPHY; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; ANTAGONISTS AND INHIBITORS; CHOROIDAL NEOVASCULARIZATION; DRUG EFFECTS;

RATTUS;

ANIMALS; CHOROIDAL NEOVASCULARIZATION; CYCLOOXYGENASE 2; DISEASE PROGRESSION; FLUORESCEIN ANGIOGRAPHY; GENE EXPRESSION REGULATION; MALE; MATRIX METALLOPROTEINASE 2; PEPTIDE FRAGMENTS; PEPTIDES; PHOSPHORYLATION; RATS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84878620378     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065434     Document Type: Article

References (42)

1. Fine SL, Berger JW, Maguire MG, Ho AC, (2000) Age-related macular degeneration. N Engl J Med 342: 483-492.
2. Campochiaro PA, (2000) Retinal and choroidal neovascularization. J Cell Physiol 184: 301-310.
3. Arnold JJ, Sarks SH, (2000) Extracts from "clinical evidence": age related macular degeneration. BMJ 321: 741-744.
4. Yoshida T, Ohno-Matsui K, Yasuzumi K, Kojima A, Shimada N, et al. (2003) Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology 110: 1297-1305.
5. Grossniklaus HE, Green WR, (1992) Pathologic findings in pathologic myopia. Retina 12: 127-133.
6. Klein R, Klein BE, Jensen SC, Cruickshanks KJ, (1998) The relationship of ocular factors to the incidence and progression of age-related maculopathy. Arch Ophthalmol 116: 506-513.
7. Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, et al. (1995) An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 39: 367-374.
8. Bhutto IA, McLeod DS, Hasegawa T, Kim SY, Merges C, et al. (2006) Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration. Exp Eye Res 82: 99-110.
9. Lu M, Adamis AP, (2006) Molecular biology of choroidal neovascularization. Ophthalmol Clin North Am 19: 323-334.
10. Schlingemann RO, (2004) Role of growth factors and the wound healing response in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 242: 91-101.
11. Ip MS, Scott IU, Brown GC, Brown MM, Ho AC, et al. (2008) Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology. Ophthalmology 115: 1837-1846.
12. Brown DM, Regillo CD, (2007) Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol 144: 627-637.
13. Konstantinidis L, Mantel I, Pournaras JA, Zografos L, Ambresin A, (2009) Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 247: 311-318.
14. Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, et al. (2010) Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ 340: c2459.
15. Watanabe D, Takagi H, Suzuma K, Oh H, Ohashi H, et al. (2005) Expression of connective tissue growth factor and its potential role in choroidal neovascularization. Retina 25: 911-918.
16. Nagineni CN, Samuel W, Nagineni S, Pardhasaradhi K, Wiggert B, et al. (2003) Transforming growth factor-beta induces expression of vascular endothelial growth factor in human retinal pigment epithelial cells: involvement of mitogen-activated protein kinases. J Cell Physiol 197: 453-462.
17. Amin R, Puklin JE, Frank RN, (1994) Growth factor localization in choroidal neovascular membranes of age-related macular degeneration. Invest Ophthalmol Vis Sci 35: 3178-3188.
18. Ogata N, Yamamoto C, Miyashiro M, Yamada H, Matsushima M, et al. (1997) Expression of transforming growth factor-beta mRNA in experimental choroidal neovascularization. Curr Eye Res 16: 9-18.
19. Bian ZM, Elner SG, Elner VM, (2007) Regulation of VEGF mRNA expression and protein secretion by TGF-beta2 in human retinal pigment epithelial cells. Exp Eye Res 84: 812-822.
20. Recalde S, Zarranz-Ventura J, Fernandez-Robredo P, Garcia-Gomez PJ, Salinas-Alaman A, et al. (2011) Transforming growth factor-beta inhibition decreases diode laser-induced choroidal neovascularization development in rats: P17 and P144 peptides. Invest Ophthalmol Vis Sci 52: 7090-7097.
21. Lee E, Rewolinski D, (2010) Evaluation of CXCR4 inhibition in the prevention and intervention model of laser-induced choroidal neovascularization. Invest Ophthalmol Vis Sci 51: 3666-3672.
22. Garcia-Layana A, Vasquez G, Salinas-Alaman A, Moreno-Montanes J, Recalde S, et al. (2009) Development of laser-induced choroidal neovascularization in rats after retinal damage by sodium iodate injection. Ophthalmic Res 42: 205-212.
23. Santiago B, Gutierrez-Canas I, Dotor J, Palao G, Lasarte JJ, et al. (2005) Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis. J Invest Dermatol 125: 450-455.
24. Ezquerro IJ, Lasarte JJ, Dotor J, Castilla-Cortazar I, Bustos M, et al. (2003) A synthetic peptide from transforming growth factor beta type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury. Cytokine 22: 12-20.
25. Dotor J, Lopez-Vazquez AB, Lasarte JJ, Sarobe P, Garcia-Granero M, et al. (2007) Identification of peptide inhibitors of transforming growth factor beta 1 using a phage-displayed peptide library. Cytokine 39: 106-115.
26. Serrati S, Margheri F, Pucci M, Cantelmo AR, Cammarota R, et al. (2009) TGFbeta1 antagonistic peptides inhibit TGFbeta1-dependent angiogenesis. Biochem Pharmacol 77: 813-825.
27. Vicent S, Luis-Ravelo D, Anton I, Garcia-Tunon I, Borras-Cuesta F, et al. (2008) A novel lung cancer signature mediates metastatic bone colonization by a dual mechanism. Cancer Res 68: 2275-2285.
28. Hermida N, Lopez B, Gonzalez A, Dotor J, Lasarte JJ, et al. (2009) A synthetic peptide from transforming growth factor-beta1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats. Cardiovasc Res 81: 601-609.
29. Gil-Guerrero L, Dotor J, Huibregtse IL, Casares N, Lopez-Vazquez AB, et al. (2008) In vitro and in vivo down-regulation of regulatory T cell activity with a peptide inhibitor of TGF-beta1. J Immunol 181: 126-135.
30. Merrifield R, (1963) Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J Am Chem Soc 85: 2149-2154.
31. Atherton E, Logan J, Sheppard R, (1989) Peptide synthesis. II. Procedures for solid phase synthesis using N-fluorenyl methoxycarbonyl aminoacids on polyamide supports. Sintesis of substance P and of acyl carrier protein 65-74 decapeptide. J Chem Soc Perkin Trans 1: 538-546.
32. Kim SJ, Toma HS, Barnett JM, Penn JS, (2010) Ketorolac inhibits choroidal neovascularization by suppression of retinal VEGF. Exp Eye Res 91: 537-543.
33. Green WR, (1991) Clinicopathologic studies of treated choroidal neovascular membranes. A review and report of two cases. Retina 11: 328-356.
34. Grossniklaus HE, Ling JX, Wallace TM, Dithmar S, Lawson DH, et al. (2002) Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis 8: 119-126.
35. Hollyfield JG, Bonilha VL, Rayborn ME, Yang X, Shadrach KG, et al. (2008) Oxidative damage-induced inflammation initiates age-related macular degeneration. Nat Med 14: 194-198.
36. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, et al. (2001) An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res 20: 705-732.
37. Mullins RF, Russell SR, Anderson DH, Hageman GS, (2000) Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J 14: 835-846.
38. Elner VM, Strieter RM, Elner SG, Baggiolini M, Lindley I, et al. (1990) Neutrophil chemotactic factor (IL-8) gene expression by cytokine-treated retinal pigment epithelial cells. Am J Pathol 136: 745-750.
39. Kvanta A, Algvere PV, Berglin L, Seregard S, (1996) Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 37: 1929-1934.
40. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR, (1996) Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 37: 855-868.
41. Penfold PL, Madigan MC, Gillies MC, Provis JM, (2001) Immunological and aetiological aspects of macular degeneration. Prog Retin Eye Res 20: 385-414.
42. Steen B, Sejersen S, Berglin L, Seregard S, Kvanta A, (1998) Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes. Invest Ophthalmol Vis Sci 39: 2194-2200.